As summarized in Figure 2, approximately 25% of patients with NSCLC have actionable genetic alterations, including EGFR-, BRAF V600E-, MET exon 14 splicing site-, ERBB2 (HER2)-, KRAS G12C-sensitizing mutations, and ALK-, ROS1-, RET-, and NTRK-gene fusions. Here, ERBB2 is linked to non-small cell lung carcinoma.